drug
ipilimumab
Marketedupdated 3mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
NSCLC
all catalysts(2)
Trials studying ipilimumab
- phase1NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
- phase3Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- phase1A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- phase2Pan Tumor Rollover Study
- phase2A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- phase1VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
- phase2An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
- phase2Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
News(8)
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 7d ago
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 8d ago
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 8d ago
- FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcommThe FDA's rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.biospace · 14d ago
- Scancell to go public after winning reverse merger bid for troubled NeuphoriaScancell and Neuphoria have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders after the biotech ended it…fiercebiotech · 19d ago
- Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.onclive · 3mo ago
- Dr Sznol on Biomarkers of Response in Metastatic MelanomaMario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.onclive · 3mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 3mo ago
Data sources
last refreshed 43m ago
Found something off?
comments(0)
5-min edit window · permanent after that